All feline diagnoses

Your cat was diagnosed with Cutaneous Squamous Cell Carcinoma (Non-Nasal). Second most common skin tumour in cats after mast cell tumour. Solar-induced (UV) aetiology in most cases. Progression from actinic keratosis → carcinoma in situ → invasive SCC. Most commonly affects pinna (ear tips), eyelids, and nasal planum but this entry covers non-nasal cutaneous sites. Predominantly affects white or light-pigmented cats in sun-exposed areas. Outdoor cats at higher risk. Compare 6 treatment options for cats including Surgical Excision, Radiation (Hypofractionated), Electrochemotherapy — with survival times, costs, and what to expect during treatment.

🐈

Cutaneous Squamous Cell Carcinoma (Non-Nasal)

variable

BreedsWhite cats (highest risk)Light-pigmented catsCats with white ears or facial markingsSiamese (reportedly lower risk due to pigmentation)
feline

Epithelial

About This Cancer

Cutaneous squamous cell carcinoma at sites other than the nasal planum arises from the squamous cells of the skin. Like nasal planum SCC, it can be associated with ultraviolet radiation exposure in lightly pigmented cats, particularly affecting the ear tips and eyelids. The tumour is locally invasive but tends to have a low rate of distant metastasis when found in the skin. Early diagnosis and complete surgical removal offer the best outcomes, and most cats with fully excised cutaneous SCC do very well. Radiation therapy and electrochemotherapy are effective alternatives or adjuncts when surgery alone cannot achieve clean margins. With timely diagnosis and complete removal, the prognosis for cutaneous SCC at these sites is generally favourable.

Prognostic Factors(5)
Anatomical locationPinna SCC has excellent prognosis with pinnectomy (>90% cure). Periocular and digital sites also amenable to surgery. Diffuse/multifocal disease carries worse prognosis.
T stage / depth of invasionSuperficial (T1) tumours have dramatically better outcomes than deeply invasive (T3-T4) lesions. Depth determines eligibility for plesiotherapy and cryotherapy.
Solar-induced vs non-solar aetiologySolar-induced SCC (actinic) is more common and follows predictable progression. Non-solar SCC may be more aggressive. Papillomavirus-associated Bowen's disease is a distinct entity.
Margin statusComplete excision with clean margins is the strongest predictor of cure. Incomplete margins significantly increase recurrence risk.
Completeness of excisionComplete excision results in excellent prognosis
Minimum Workup(4 steps)
1Biopsy with histopathology
2Regional lymph node assessment
3Thoracic radiographs
4CBC, chemistry panel

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Surgical Excision
See notes
Radiation (Hypofractionated)
See notes
Electrochemotherapy
See notes
Cryotherapy
See notes
Strontium-90 Plesiotherapy
See notes
Palliation / Supportive Care
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.